Pfizer (NYSE:PFE) is looking to expand the use of the antiviral Paxlovid, which FDA has authorized to treat mild-to-moderate COVID-19 in individuals who are at least 12 years of age who weigh at least 40 kg. The authorization covers individuals with a risk of developing severe disease.
A recently launched Phase 2/3 study will test Paxlovid in non-hospitalized symptomatic pediatric patients with COVID-19. Known as EPIC-PEDS (Evaluation of Protease Inhibition for COVID-19 in Pediatric Patients), the study will focus on patients at risk of developing severe COVID-19.
“We are proud to expand studies of our novel COVID-19 treatment to include pediatric participants to further evaluate the safety and efficacy of this treatment in this important population,” said Mikael Dolsten, Pfizer’s chief scientific officer at Pfizer.
The EPIC-PEDS study will be an open-label, multi-center, single-arm study involving roughly 140 pediatric participants under 18 years of a…